Zacks Research Upgrades Nutriband (NASDAQ:NTRB) to Hold

Nutriband (NASDAQ:NTRB) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other analysts have also recently commented on the company. Wall Street Zen cut Nutriband from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nutriband in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nutriband currently has an average rating of “Hold” and an average price target of $13.00.

Nutriband Stock Performance

Shares of NASDAQ:NTRB traded down $0.22 during midday trading on Tuesday, reaching $5.64. The company’s stock had a trading volume of 18,758 shares, compared to its average volume of 113,210. The firm has a market capitalization of $67.88 million, a PE ratio of -1.97 and a beta of 1.54. The stock has a fifty day moving average of $6.97 and a 200 day moving average of $7.06. The company has a quick ratio of 4.70, a current ratio of 4.78 and a debt-to-equity ratio of 0.01. Nutriband has a twelve month low of $3.72 and a twelve month high of $11.78.

Nutriband (NASDAQ:NTRB) last posted its earnings results on Tuesday, September 9th. The company reported ($2.12) EPS for the quarter, missing the consensus estimate of ($0.17) by ($1.95). The company had revenue of $0.62 million for the quarter, compared to analyst estimates of $0.71 million. Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%. On average, equities analysts expect that Nutriband will post -0.6 EPS for the current fiscal year.

Institutional Trading of Nutriband

Several hedge funds have recently modified their holdings of NTRB. US Bancorp DE acquired a new position in Nutriband during the 1st quarter worth approximately $29,000. Consolidated Portfolio Review Corp acquired a new position in shares of Nutriband during the second quarter worth $81,000. Finally, Vanguard Group Inc. grew its stake in shares of Nutriband by 1.6% during the third quarter. Vanguard Group Inc. now owns 202,738 shares of the company’s stock worth $1,429,000 after purchasing an additional 3,111 shares in the last quarter. 19.70% of the stock is currently owned by institutional investors and hedge funds.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.